Entrada Therapeutics (TRDA) Insider Sells 1,746 Shares to Cover RSU Taxes

Q: What did Nathan J. Dowden report on Form 4 for TRDA?

He reported a sale of 1,746 shares of Entrada Therapeutics common stock on 09/02/2025 to cover tax withholding from vested RSUs.

Q: At what price were the TRDA shares sold according to the filing?

The filing lists a weighted average price of $5.4302 and states the shares were sold at prices ranging from $5.36 to $5.58 .

Q: How many TRDA shares does Dowden beneficially own after the reported sale?

The filing reports 179,059 shares beneficially owned following the transaction.

Q: Why were the shares sold according to the Form 4 explanation?

The sale was made to cover tax withholding obligations arising from the vesting of previously granted restricted stock units (RSUs).

Q: Who signed the Form 4 filing for this transaction?

The filing is signed by /s/ Jared Cohen, as Attorney-in-Fact and dated 09/04/2025 .

[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Entrada Therapeutics insider sale to cover RSU taxes The filing shows Nathan J. Dowden, President & COO of Entrada Therapeutics (TRDA), reported a sale of 1,746 shares of common stock on 09/02/2025 at a weighted average price of $5.4302. After the sale he beneficially owned 179,059 shares. The filing states the sale was to satisfy tax withholding obligations arising from vested restricted stock units and was executed in multiple transactions at prices ranging $5.36 to $5.58.

Positive

Transaction disclosed promptly and transparently with price range and weighted average provided
Sale was for tax withholding on vested RSUs, a routine administrative action rather than a compensation-related cash-out

Negative

None.

Insights

TL;DR: Routine insider sale to cover RSU tax withholding; small in size relative to total outstanding shares and not indicative of company-wide change.

The reported disposition of 1,746 shares by the President & COO is explicitly described as a tax-withholding sale tied to vested RSUs. The weighted average sale price of $5.4302 and the disclosed price range provide transparency on execution. Given the post-transaction holding of 179,059 shares, this transaction appears administrative rather than a signal of shifting insider conviction. No derivative transactions or additional departures were reported.

TL;DR: Filing reflects compliance with Section 16 reporting; transaction aligns with common equity compensation practices.

The Form 4 is properly filed and signed via attorney-in-fact, documenting the officer-level sale for tax purposes. The explanation clarifies the sale covered withholding for vested RSUs and offers to provide detailed execution information upon request, which supports transparency. There is no indication of material governance events or unusual trading patterns in this disclosure.

09/04/2025 - 05:03 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dowden Nathan J

(Last)

(First)

(Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON

02210

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & COO

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/02/2025		F		1,746⁽¹⁾	D	$5.4302⁽²⁾	179,059	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.36 to $5.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What did Nathan J. Dowden report on Form 4 for TRDA?

He reported a sale of 1,746 shares of Entrada Therapeutics common stock on 09/02/2025 to cover tax withholding from vested RSUs.

At what price were the TRDA shares sold according to the filing?

The filing lists a weighted average price of $5.4302 and states the shares were sold at prices ranging from $5.36 to $5.58.

How many TRDA shares does Dowden beneficially own after the reported sale?

The filing reports 179,059 shares beneficially owned following the transaction.

Why were the shares sold according to the Form 4 explanation?

The sale was made to cover tax withholding obligations arising from the vesting of previously granted restricted stock units (RSUs).

Who signed the Form 4 filing for this transaction?

The filing is signed by /s/ Jared Cohen, as Attorney-in-Fact and dated 09/04/2025.

AG真人官方

[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Insights

FAQ

What did Nathan J. Dowden report on Form 4 for TRDA?

At what price were the TRDA shares sold according to the filing?

How many TRDA shares does Dowden beneficially own after the reported sale?

Why were the shares sold according to the Form 4 explanation?

Who signed the Form 4 filing for this transaction?

NASDAQ:TRDA

TRDA Rankings

TRDA Latest News

TRDA Latest SEC Filings

TRDA Stock Data

AG真人官方

Trending News

[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity

Insights

Financial Analyst neutral

Corporate Governance Expert neutral

FAQ

What did Nathan J. Dowden report on Form 4 for TRDA?

At what price were the TRDA shares sold according to the filing?

How many TRDA shares does Dowden beneficially own after the reported sale?

Why were the shares sold according to the Form 4 explanation?

Who signed the Form 4 filing for this transaction?

NASDAQ:TRDA

TRDA Rankings

TRDA Latest News

TRDA Latest SEC Filings

TRDA Stock Data